SEC Form 3 · accession 0001354488-16-008088
Cellular Biomedicine Group, Inc. · CBMG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Zhou Hansheng
Director
Period of report
Jul 8, 2016
Accepted (ET)
Jul 18, 2016 · 8:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001378624
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.001F1 | holding | — | — | — | 2,270,000 | I | By Dangdai International Group Co. |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy) (2014 Plan) | $16.00 | holding | — | — | — | Jul 18, 2017 | Jul 18, 2026 | Common Stock | 5,300 | — | D |
Explanation of responses
- F1The number of shares reported is greater than the reporting person?s pecuniary interest in the issuer?s common stock held by Dangdai International Group Co.